Sensitivity of Nakahara-Fukuoka sarcoma to antitumor agents, especially to purine analogs.
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002066:Busulfan / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000627:therapeutic use; D005260:Female; D005472:Fluorouracil / Q000627:therapeutic use; D006854:Hydrocortisone / Q000627:therapeutic use; D008466:Mechlorethamine / Q000627:therapeutic use; D015122:Mercaptopurine / Q000627:therapeutic use; D008727:Methotrexate / Q000627:therapeutic use; D051379:Mice; D008937:Mitomycins / Q000627:therapeutic use; D011687:Purines / Q000627:therapeutic use*; D012513:Sarcoma, Experimental / Q000188:drug therapy*; D013866:Thioguanine / Q000627:therapeutic use; D013852:Thiotepa / Q000627:therapeutic use; D014498:Uracil / Q000031:analogs & derivatives / Q000627:therapeutic use
D000970:Antineoplastic Agents; D008937:Mitomycins; D011687:Purines; D008466:Mechlorethamine; D014498:Uracil; D003520:Cyclophosphamide; D013852:Thiotepa; D015122:Mercaptopurine; D013866:Thioguanine; D002066:Busulfan; D005472:Fluorouracil; D006854:Hydrocortisone; D008727:Methotrexate